Alcohol

More documents

Recommendations

Info

Post-Shock Drinking 25 20 15 10 Placebo Naltrexone 5 0 -5 1-2 3-4 5-6 Days Post-Shock
Page 1 and 2: The Path to Genomic Medicine For Ad
Page 3 and 4: Use Use Use Use Use Abuse (declarat
Page 5 and 6: Possible Changes • Addiction inst
Page 7 and 8: Addiction: Loss of control • Jean
Page 9 and 10: Possible Families of Risk Factors
Page 11 and 12: Response • Genetically influenced
Page 13 and 14: Drugs of Abuse all Activate Reward
Page 15 and 16: Effects of Drugs on Dopamine Levels
Page 17 and 18: Relationship between Cue-Induced De
Page 19: “Unseen” Reward Cues activate a
Page 22 and 23: Alcoholism: FDA Approved Medication
Page 24 and 25: Alcohol - Beverage Condition Cingul
Page 26 and 27: Baclofen blunts Amygdala Connectivi
Page 28 and 29: Alcohol reward Sedating drug, facil
Page 30 and 31: True Translational Story: Naltrexon
Page 32: Naltrexone decreases Alcohol prefer
Page 39 and 40: Variable response to alcohol Alcoho
Page 41 and 42: Pre-Alcohol “Craving” 150 140 1
Page 43 and 44: Dopamine Long Loop Dopamine - Nucle
Page 45 and 46: Consistent effects of opioid antago
Page 47 and 48: Opiate Receptors N Post-Synaptic Ne
Page 49 and 50: Receptor Blockade with Naltrexone (
Page 51 and 52: Double blind design • 70 chronic
Page 53 and 54: Measures of Craving • 100 mm Visu
Page 55 and 56: Any Alcohol Drinking 80 60 40 20 0
Page 57 and 58: Subjective “high” in Naltrexone
Page 59 and 60: Non-relapse “Survival” Cummulat
Page 61 and 62: Alcohol “PRIMING” in human, non
Page 63 and 64: Studies supporting efficacy Studies
Page 65 and 66: Why do many alcoholics respond to n
Page 67 and 68: Family History and Naltrexone Effic
Page 69 and 70: Change in b- Endorphin Levels after
Page 71 and 72: What is Transducer • Alcohol rele
Page 73 and 74: OPRM1 PROTEIN STRUCTURE EXTRACELLUL
Page 75 and 76: Functional Allele Increase and Decr
Page 77 and 78: Zhang et al, JBC, 2005 OPRM1 A118G
Page 79 and 80: Wand et al, Neuropsychopharm 26:106
Page 81 and 82: Alcohol effects by genotype 50 45 4
Page 83 and 84:
OPRM1 A118G and Opioid Dependence B
Page 85 and 86:
Relapse Rate by Genotype 1.0 .9 Pro
Page 87 and 88:
Combine: NIAAA Good Outcome Nalt A/
Page 89 and 90:
Sub-sample of VA coop. study Those
Page 91 and 92:
Possible Gender Effect Males more r
Page 93 and 94:
Best Treatment • Medications Plus
Page 95 and 96:
Penn/VA Center Team Joe Volpicelli
Page 97:
Learning Objectives • Describe th
show all

Alcohol

Create successful ePaper yourself

Delete template?

Save as template?